Hughes Biotechnology

Water soluble. Easily absorbed
World-leading polyphenols for precision health

Hughes proudly swept multiple Gold Medals at international invention expos

RenoFlavone™

370% | *Most bioavilable genistein supporting menopause women health*



- 100,000X Aqueous solubility
- 3.7X Superior bioavailability
- Clinical proven efficacy
- International innovation gold awards
- US FDA New Dietary Ingredient (1283)
- Global patents in five countries

High solubility
High bioavailability

15 MIN
Small molecule
Fast absorption

Efficient delivery
Maximum efficacy

RenoFlavone™ — a breakthrough fermented soy extract powered by RenoSorb™ postbiotic exo-delivery technology. Standardized with highly water-soluble genistein phosphate, it ensures superior absorption and efficacy, unleashing nature's restorative power. Clinically proven to support women's wellness, RenoFlavone™ helps ease menopausal and premenstrual discomfort. Among the twelve natural isoflavones, genistein is the most potent phytoestrogen, showing high ERβ/ERα affinity that promotes feminine vitality.



Genistein phosphate

RenoFlavone™

Most bioavilable genistein supporting menopause women health

MENOPAUSE SUPPORT | PMS RELIEF | BONE HEALTH | HEART HEALTH

RenoSorb™ Technology platform

From Solid to Liquid

Next Generation pharma-grade postbiotics exo-precursor delivery technology



2025 Gold Award Winner, Taipei Biotech Awards — The Biotech Oscars "Innovative Technology Award (Applied Biotechnology)"

2023 Top 5 Global Finalist, Vitafoods Europe Startup Challenge Award "Most Innovative Technology Supporting the Nutraceutical Industry"

Pharmacokinetic profile

3.7x better absorption



Mean plasma concentration-time profiles of genistein in rats after oral adminstration of native genistein and RenoFlavone™ at 3.7 μmol/kg bw. Data are mean ± SE (n = 4).

Journal of Functional Foods 13 (2015): 323-335.

Animal study

Postmenopausal bone health



Osteoprotective effect of RenoFlavone™, containing genistein derivatives with high bioavailability, in ovariectomized rats. Micro-CT analysis of effect of treatments on femoral metaphysis of ovariectomized rats. BMD of placebo and RenoFlavone™ group (15.2 μmol/kg bw/day) after 12-week treatment.
Data are mean ± SD, n = 6. Value are mean ± SEM. **p < 0.01. RenoFlavone™ vs placebo group (paired t-test).

Journal of Functional Foods 58 (2019): 171-179.

Clinical study

Relieve PMS discomfort



A randomized controlled trial of RenoFlavone™ in the treatment of primary dysmenorrhea. Effects of RenoFlavoneTM (20 mg/day) and placebo on menstrual pain score (Short form McGill pain questionnaire score, SF-MPQ) in first month (The trial is ongoing). Value are mean ± SEM, n = 40. Comparison of changes between the study groups (chi-square test). ***p < 0.001.

Unpublished data

Recommended dose: 40-80 mg

Capsules | Tablets | Effervescent tablets | Powder | Gummies | Beverages | Pets

ISO 22000 | HALAL | Vegan | GMO | Gluten | ETO

Hughes Biotechnology Co., Ltd.

ADD 12F.-2, No.420, Sec.1, Keelung Rd., Xinyi Dist., Taipei City 110, Taiwan
TEL +886-2-2758-2232
WEB http://www.hughesbiotech.com/
MAIL service@hughesbiotech.com

Hughes Biotechnology